Network News

TRANSVAC: a pillar of vaccine development in Europe for 16 years

TRANSVAC: a pillar of vaccine development in Europe for 16 years

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

Gyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

Gyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

EU-OPENSCREEN announces new service category: Chemoproteomics and Spatial MS-Based Omics

EU-OPENSCREEN announces new service category: Chemoproteomics and Spatial MS-Based Omics

YUMAB and InSCREENeX are developing an innovative “Mammalian Display” screening platform to accelerate antibody development.

YUMAB and InSCREENeX are developing an innovative “Mammalian Display” screening platform to accelerate antibody development.

New weapons against viruses

New weapons against viruses

BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial

BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy